Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Coronado Biosciences Inc's Business Segments
Coronado Biosciences Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
2
Largest Segment
Journey
Total Revenue
$ 16
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Journey99.5%
- Fortress Biotech Inc0.5%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Journey | $ 16 | 99.5% |
| Fortress Biotech Inc | $ 0 | 0.5% |
Revenue by Product & Service Category - Q1 FY2026
- Emrosi39%
- Qbrexza31.4%
- Accutane20.7%
- Foam Franchise Products6.5%
- Other legacy product revenue1.7%
- Royalty0.5%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Emrosi | $ 6 | 39% |
| Qbrexza | $ 5 | 31.4% |
| Accutane | $ 3 | 20.7% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
3 more categories available
Sign in to unlock the full Coronado Biosciences Inc dataset.
Description of Coronado Biosciences Inc
Coronado Biosciences Inc. is a biopharmaceutical company that focuses on the development of novel immunotherapy products for the treatment of certain autoimmune disorders and cancer. The company was founded in 2006 and is headquartered in Burlington, Massachusetts, United States.
The primary goal of Coronado Biosciences is to improve the lives of patients suffering from immune-mediated diseases by targeting the underlying cause of the disorder rather than just alleviating symptoms. The company utilizes its innovative proprietary technology platform to develop biotherapeutic products, specifically utilizing the power of the immune system to combat diseases.
Coronado Biosciences has a strong research and development pipeline that includes both preclinical and clinical stage programs. The company's most advanced product candidate is CNDO-109, a biologic medication being developed for the treatment of acute myeloid leukemia (AML). CNDO-109 is a monoclonal antibody that targets leukemic stem cells, which are responsible for the recurrence of AML after initial treatment.
In addition to AML, Coronado Biosciences is also exploring the potential of its immunotherapy platform in other diseases such as Crohn's disease, ulcerative colitis, and multiple sclerosis. The company's approach involves the use of specialized cells, such as regulatory T cells, to modulate the immune response and restore immune homeostasis in patients.
The immunotherapy products developed by Coronado Biosciences are aimed at providing more targeted and effective treatments with fewer side effects compared to traditional pharmaceutical interventions. The company’s focus on immunotherapy aligns with the growing trend in the biopharmaceutical industry towards personalized medicine, where therapies are tailored to individual patients based on their genetic makeup and disease characteristics.
To support its research and development efforts, Coronado Biosciences collaborates with leading academic institutions, clinical research organizations, and pharmaceutical companies. These collaborations help in advancing the company's product candidates through clinical trials and expanding the understanding of the underlying mechanisms driving diseases.
Overall, Coronado Biosciences Inc. is a biopharmaceutical company dedicated to developing innovative immunotherapy products for the treatment of autoimmune disorders and cancer. With a strong pipeline of promising therapeutic candidates and strategic collaborations, the company aims to make a significant impact on patient care in areas with significant medical unmet needs.
The primary goal of Coronado Biosciences is to improve the lives of patients suffering from immune-mediated diseases by targeting the underlying cause of the disorder rather than just alleviating symptoms. The company utilizes its innovative proprietary technology platform to develop biotherapeutic products, specifically utilizing the power of the immune system to combat diseases.
Coronado Biosciences has a strong research and development pipeline that includes both preclinical and clinical stage programs. The company's most advanced product candidate is CNDO-109, a biologic medication being developed for the treatment of acute myeloid leukemia (AML). CNDO-109 is a monoclonal antibody that targets leukemic stem cells, which are responsible for the recurrence of AML after initial treatment.
In addition to AML, Coronado Biosciences is also exploring the potential of its immunotherapy platform in other diseases such as Crohn's disease, ulcerative colitis, and multiple sclerosis. The company's approach involves the use of specialized cells, such as regulatory T cells, to modulate the immune response and restore immune homeostasis in patients.
The immunotherapy products developed by Coronado Biosciences are aimed at providing more targeted and effective treatments with fewer side effects compared to traditional pharmaceutical interventions. The company’s focus on immunotherapy aligns with the growing trend in the biopharmaceutical industry towards personalized medicine, where therapies are tailored to individual patients based on their genetic makeup and disease characteristics.
To support its research and development efforts, Coronado Biosciences collaborates with leading academic institutions, clinical research organizations, and pharmaceutical companies. These collaborations help in advancing the company's product candidates through clinical trials and expanding the understanding of the underlying mechanisms driving diseases.
Overall, Coronado Biosciences Inc. is a biopharmaceutical company dedicated to developing innovative immunotherapy products for the treatment of autoimmune disorders and cancer. With a strong pipeline of promising therapeutic candidates and strategic collaborations, the company aims to make a significant impact on patient care in areas with significant medical unmet needs.
As of my last available information, Coronado Biosciences Inc. is a biopharmaceutical company primarily focusing on the development and commercialization of novel therapeutic agents to address various unmet medical needs, particularly in the areas of autoimmune diseases and oncology. Below is an extensive description of the segments, products, and services that the company is known for:
Segments
1. Autoimmune Diseases:
- Coronado Biosciences has focused on developing therapeutics aimed at treating autoimmune disorders. These conditions often arise when the bodys immune system mistakenly attacks its tissues, leading to a range of symptoms and complications. The company targets disorders such as multiple sclerosis, rheumatoid arthritis, and inflammatory bowel diseases.
2. Oncology:
- The company is also actively involved in oncology, developing innovative therapies that target various forms of cancer. This segment typically involves research into how the immune system can be harnessed to combat tumor cells, including the development of immunotherapies and checkpoint inhibitors.
3. Personalized Medicine:
- Coronado Biosciences places an emphasis on personalized medicine, seeking to tailor treatments based on an individuals genetic makeup and specific characteristics of their disease. This approach aims to increase the effectiveness of treatments and reduce potential side effects.
Products
1. Therapeutics in Clinical Trials:
- The cornerstone of Coronado Biosciences product portfolio includes several investigational drugs that are in various stages of clinical trials. These products are often biologics or small molecules that are designed to modulate immune responses or target specific pathways involved in disease processes.
2. CD-01:
- One product of particular note is CD-01, a promising candidate focused on treating autoimmune diseases. This compound may involve the modulation of immune responses to achieve better control over disease symptoms and progression.
3. ADC Technology:
- Coronado is also involved in the development of Antibody-Drug Conjugates (ADCs), which are targeted cancer therapies designed to deliver cytotoxic agents directly to tumor cells through conjugation with antibodies. This method can improve the precision of cancer treatments and minimize collateral damage to healthy cells.
Services
1. Research and Development:
- Coronado Biosciences invests significantly in R&D, focusing on the discovery and development of new drugs. The R&D services include preclinical studies, clinical trial design, and execution, biomarker identification, and patient stratification efforts.
2. Clinical Trials Management:
- The company may offer services related to the management of clinical trials, ensuring compliance with regulatory requirements and overseeing the progression of trials from initiation to completion. This includes site selection, patient recruitment, and data management.
3. Partnerships and Collaborations:
- Coronado Biosciences frequently engages in collaborations with academic institutions, research organizations, and pharmaceutical companies. Through these partnerships, they aim to enhance their research capabilities and accelerate the development of their drug candidates.
4. Regulatory Affairs:
- The company’s services may include navigating the complex landscape of regulatory submissions and approvals required for bringing drugs to market. This involves working closely with agencies such as the FDA, managing Investigational New Drug (IND) applications, and preparing New Drug Applications (NDAs).
5. Patient Support Programs:
- Understanding the importance of patient engagement, Coronado Biosciences may also provide support programs aimed at educating and assisting patients who are involved in clinical trials or using their products. This could include informational resources, counseling, and access to patient advocacy groups.
Overall, Coronado Biosciences Inc. exhibits a robust commitment to advancing the fields of autoimmune disorders and oncology through innovative therapies and comprehensive services. The focus on research, development, and patient-centric strategies positions the company as a noteworthy entity in the biopharmaceutical landscape.
Segments
1. Autoimmune Diseases:
- Coronado Biosciences has focused on developing therapeutics aimed at treating autoimmune disorders. These conditions often arise when the bodys immune system mistakenly attacks its tissues, leading to a range of symptoms and complications. The company targets disorders such as multiple sclerosis, rheumatoid arthritis, and inflammatory bowel diseases.
2. Oncology:
- The company is also actively involved in oncology, developing innovative therapies that target various forms of cancer. This segment typically involves research into how the immune system can be harnessed to combat tumor cells, including the development of immunotherapies and checkpoint inhibitors.
3. Personalized Medicine:
- Coronado Biosciences places an emphasis on personalized medicine, seeking to tailor treatments based on an individuals genetic makeup and specific characteristics of their disease. This approach aims to increase the effectiveness of treatments and reduce potential side effects.
Products
1. Therapeutics in Clinical Trials:
- The cornerstone of Coronado Biosciences product portfolio includes several investigational drugs that are in various stages of clinical trials. These products are often biologics or small molecules that are designed to modulate immune responses or target specific pathways involved in disease processes.
2. CD-01:
- One product of particular note is CD-01, a promising candidate focused on treating autoimmune diseases. This compound may involve the modulation of immune responses to achieve better control over disease symptoms and progression.
3. ADC Technology:
- Coronado is also involved in the development of Antibody-Drug Conjugates (ADCs), which are targeted cancer therapies designed to deliver cytotoxic agents directly to tumor cells through conjugation with antibodies. This method can improve the precision of cancer treatments and minimize collateral damage to healthy cells.
Services
1. Research and Development:
- Coronado Biosciences invests significantly in R&D, focusing on the discovery and development of new drugs. The R&D services include preclinical studies, clinical trial design, and execution, biomarker identification, and patient stratification efforts.
2. Clinical Trials Management:
- The company may offer services related to the management of clinical trials, ensuring compliance with regulatory requirements and overseeing the progression of trials from initiation to completion. This includes site selection, patient recruitment, and data management.
3. Partnerships and Collaborations:
- Coronado Biosciences frequently engages in collaborations with academic institutions, research organizations, and pharmaceutical companies. Through these partnerships, they aim to enhance their research capabilities and accelerate the development of their drug candidates.
4. Regulatory Affairs:
- The company’s services may include navigating the complex landscape of regulatory submissions and approvals required for bringing drugs to market. This involves working closely with agencies such as the FDA, managing Investigational New Drug (IND) applications, and preparing New Drug Applications (NDAs).
5. Patient Support Programs:
- Understanding the importance of patient engagement, Coronado Biosciences may also provide support programs aimed at educating and assisting patients who are involved in clinical trials or using their products. This could include informational resources, counseling, and access to patient advocacy groups.
Overall, Coronado Biosciences Inc. exhibits a robust commitment to advancing the fields of autoimmune disorders and oncology through innovative therapies and comprehensive services. The focus on research, development, and patient-centric strategies positions the company as a noteworthy entity in the biopharmaceutical landscape.